𝔖 Bobbio Scriptorium
✦   LIBER   ✦

First-line combination chemotherapy with mitoxantrone and cyclophosphamide in advanced breast cancer

✍ Scribed by P. Periti; G. Robustelli Delia Cuna; F. Pannuti; T. Mazzei; P. Preti; A. Martoni; E. Mini

Publisher
Springer US
Year
1985
Tongue
English
Weight
312 KB
Volume
3
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

✦ Synopsis

In this study, 30 evaluable patients with advanced carcinoma of the breast were treated with cyclophosphamide 600 mg/m2 i.v. followed one day later with mitoxantrone (Novantrone; dihydroxyanthracenedione) 16 mg/m2 i.v. Drug treatment was repeated every 3-4 weeks, for a maximum of 12 cycles. The overall response rate was 43%; five of 30 patients (16%) attained a complete remission, and eight of 30 (27%) had a partial remission. Median response duration was 12+ months. The greater number of responses was seen in skin and soft tissues. Hematologic toxicity was limiting with 75% of patients experiencing substantial-severe leukopenia. Clinically evident heart failure developed in one patient; in three other patients there was minor-moderate alteration of cardiac function during mitoxantrone-cyclophosphamide therapy. Based on these data, it is believed that this regimen may provide significant long-lasting palliation in patients with advanced breast cancer.

πŸ“œ SIMILAR VOLUMES

Mitoxantrone combined to vincristine, cy
Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer
✍ R. Metz; M. Delgado; R. Keiling; P. Cappelaere; J. P. Armand; G. Prevot; J. L. M πŸ“‚ Article πŸ“… 1985 πŸ› Springer US 🌐 English βš– 301 KB

In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on

Mitoxantrone as first-line chemotherapy
Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study
✍ H. T. Mouridsen; Michael Cornbleet; Robin Stuart-Harris; Ian Smith; Robert Colem πŸ“‚ Article πŸ“… 1985 πŸ› Springer US 🌐 English βš– 565 KB

Mitoxantrone (Novantrone| dihydroxyanthracenedione) is a substituted anthraquinone with a spectrum of activity similar to doxorubicin in experimental tumors. One hundred and seventy three patients with advanced breast cancer and no prior cytotoxic therapy for advanced disease entered a phase II stu